Commentary

Podcast

Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management

Author(s):

Fact checked by:

Dr Chiang discusses the use of lurbinectedin in small cell lung cancer and tips for managing toxicities associated with this agent.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by Jazz Pharmaceuticals, we had the pleasure of speaking with Anne Chiang, MD, PhD, about the use of lurbinectedin (Zepzelca) in the management of small cell lung cancer (SCLC). Dr Chiang is an associate professor of medicine in the Section of Medical Oncology at the Yale School of Medicine, as well as the associate director of Clinical Initiatives at the Yale Cancer Center in New Haven, Connecticut.

In our exclusive interview, Dr Chiang discussed key efficacy findings with lurbinectedin in the second-line SCLC setting, tips for managing toxicities associated with this agent, and how lurbinectedin fits into the SCLC treatment paradigm.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, supported by Jazz Pharmaceuticals. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
David Rimm, MD, PhD
A panel of 3 experts on nasopharyngeal carcinoma
David Rimm, MD, PhD
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma